Cleerly Uses an AI-Based Digital Platform to Transform Heart Disease Diagnosis

Cleerly is a digital health care company striving to create a new standard of care for the diagnosis of heart disease. The company uses clinically proven, artificial-intelligence-based digital care platform technologies that work with imaging to accurately detect atherosclerosis earlier and enable personalized, life-saving treatment plans.

DocWire News spoke with James K. Min, MD, founder and CEO of Cleerly, at the American Heart Association’s Scientific Sessions 2023. Dr. Min discussed the company’s mission and capabilities, as well as the announcement of the Cleerly-sponsored TRANSFORM trial, which aims to prove that a personalized care strategy based on a Cleerly analysis is superior to usual care for the primary prevention of cardiovascular events.